Third Annual CUA Astellas Research Grant Recipients Announced
MARKHAM, ON, Sept. 12, 2014 /CNW/ - The Canadian Urological Association (CUA) and Astellas Pharma Canada, Inc. (Astellas) are proud to announce the recipients of the third annual CUA Astellas Research Grant Program.
In 2012, Astellas pledged $750,000 over a period of five years to the program, which supports Canadian peer-reviewed urology research, with the ultimate goal of improving patient care.
"The Canadian researchers awarded with CUA-Astellas research grants have exceptional ideas that have the potential to make significant contributions to the lives of patients and the urological medical community," said Dr. Ricardo A. Rendon, Chair of the Scientific Council of the Canadian Urological Association Scholarship Foundation (CUASF). "Over the past two years, the substantial contributions of past recipients are already having a remarkable impact on improving understanding and treatment of functional urological conditions. We are eager to see where the visionary research of this year's recipients and future recipients lead."
This year, 11 research proposals for the 2014 CUA-Astellas Research Grant Program were reviewed by an independent committee comprised of nine medical researchers and one external reviewer, and chaired by Dr. Ricardo A. Rendon. We are pleased to announce the 2014 recipients, who include:
Dr. Luis Braga
McMaster University
Continuous antibiotic prophylaxis versus placebo in infants diagnosed with primary megaureter: A prospective randomized controlled trial
Dr. Dirk Lange
University of British Columbia
Identifying differences in intestinal microbial composition between patients with recurrent kidney stone disease and on stone-forming control
Dr. Andrea Lantz
Dalhousie University
Ureteral stent-related pain and Mirabegron (SPAM) trial
"We are excited to continue our sponsorship of the CUA Astellas Research Grant Program and our partnership with the Canadian Urological Association," said Michael Tremblay, President, Astellas Pharma Canada. "This innovative research has the potential to lead to important discoveries which can improve the quality of life for Canadian patients."
About the Canadian Urological Association (CUA)
The CUA mission is to represent and provide a voice for all Canadian urologists and to foster dedication of all members of the profession toward ensuring the highest possible standard of urologic care for Canadians.
The goals of the CUA are:
- To foster and promote excellence in urologic practice through education and research.
- To provide leadership in promoting evidence based clinical practice through the development of practice guidelines.
- To foster and promote life-long learning by Canadian urologists through continuous professional development.
- To provide leadership in public education for urologic diseases.
- To represent Canadian urology in developing and fostering partnerships while maintaining the highest educational and ethical standards.
- To represent the Canadian urologic community in relationships with national and international medical societies.
More information about CUA can be found at www.cua.org
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In Canada, Astellas has an intense commercial focus on five therapeutic areas – Urology, Immunology, Infectious Disease, Dermatology and Oncology.
For more information about Astellas Pharma Canada, Inc., please visit the corporate website: www.astellas.ca
SOURCE: Astellas Pharma Canada, Inc.
Catherine Millar, Canadian Urological Association, (514) 395-0376, [email protected]; Michelle Reale, Corporate Communications, Astellas Pharma Canada, Inc., (905) 946-5621,[email protected]
Share this article